April 30th 2025
AbbVie secures FDA approval for Rinvoq as the first oral Janus kinase inhibitor indicated for giant cell arteritis, expanding its immunology portfolio and signaling strategic growth opportunities in underserved autoimmune markets.
FDA Investigating Risk of Secondary Cancers in Patients Administered CAR T-Cell Therapy
November 29th 2023The FDA will investigate all currently approved CAR T-cell treatments, as well as BCMA-directed and CD19-directed genetically modified autologous CAR T-cell therapies, for the risk of secondary T-cell malignancies.
Concerns Raised Over False Claims in Direct-to-Consumer Online Marketing of Ketamine
November 8th 2023The online promotion of intravenous infusions and oral forms of subanesthetic ketamine for the treatment of mental health conditions has been found to frequently carry misleading or false information.
Q&A with Amy West, Head of US Digital Health & Innovation Strategy at Novo Nordisk
October 25th 2023Amy West, Head of US Digital Health & Innovation Strategy at Novo Nordisk, shares her insights on fostering collaboration, embracing change, and her compelling vision to revolutionize digital transformation and innovation in the field of healthcare.
Drug Pricing from a Legal Perspective & IRA Predictions
July 28th 2023In this exclusive Q&A, Alice Valder Curran, life sciences regulatory expert and partner, Hogan Lovells LLP, shares her perspective on the biggest drug pricing challenges today, current efforts to lower drug pricing, and the Inflation Reduction Act.